ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the ...

WASHINGTON & OXFORD, England--(BUSINESS WIRE)--Perspectum announced two research studies that were recently published, bringing hope to people with metabolic dysfunction-associated steatohepatitis ...

Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ANN ARBOR, ...

A new editorial was published in Oncotarget, Volume 16, on April 4, 2025, titled "Deep learning-based uncertainty quantification for quality assurance in hepatobiliary imaging-based techniques." Dr.

Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ENDRA Life Sciences Inc ...

Never-before-seen 3D reconstructions of human liver tissue have been created at a cellular level. The details obtained by a team of UW Medicine and University of Washington engineers and physicians ...

ENDRA Life Sciences has reported results from a clinical study showing the Taeus Liver device’s high measurement consistency in metabolic dysfunction-associated steatotic liver disease (MASLD). The ...

Ultrasound is currently the standard imaging tool for HCC surveillance. However, prior evidence has suggested that contrast-enhanced MRI—particularly with gadoxetate disodium—may detect tumors more ...